Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Molecular Partners

< Previous 1 2 Next >
Molecular Partners Reports Q3 2025 Financial Results and Clinical Progress, with DLL3-Targeting Radio-DARPin MP0712 Phase 1 Launch Expected in 2025
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
Molecular Partners reports financial results and highlights recent clinical pipeline progress for H1 2025
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
Molecular Partners appoints Martin Steegmaier as Chief Scientific Officer to drive discovery of next-gen DARPin therapeutics
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
Molecular Partners and Orano Med present preclinical data on mesothelin-targeting Radio-DARPin candidate MP0726 at SNMMI 2025
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
Molecular Partners presents positive data from ongoing Phase 1/2a trial of MP0533 in AML at EHA 2025
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
Molecular Partners Announces Planned Operational Efficiencies and Extension of Cash Runway
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
Molecular Partners to Present at Upcoming Investor Conferences
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
Molecular Partners Reports Financial Results and Highlights from Q1 2025
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
Molecular Partners presents new preclinical data on Radio-DARPin and Switch-DARPin programs at AACR 2025
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
Molecular Partners Announces all Board Proposals Approved at Annual General Meeting
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
Molecular Partners to hold three poster presentations at AACR 2025
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
Molecular Partners Publishes Invitation to Annual General Meeting 2025
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
Molecular Partners Reports Highlights from Q4 2024 and Key Financials for Full Year 2024
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
Molecular Partners Announces Participation at Upcoming Investor Conferences and 2024 Financial Results Conference Call
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
Molecular Partners and Orano Med expand partnership to develop Targeted Alpha Radio-Therapies for cancer
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
Molecular Partners Outlines Clinical Expansion Plans and Strengthens Radiopharma Strategic Focus for 2025 at 43rd Annual J.P. Morgan Healthcare Conference
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
Molecular Partners to Present at JP Morgan Healthcare Conference and Baader Helvea Swiss Equities Conference in January
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
Molecular Partners Presents Clinical Data Supporting its Ongoing MP0533 Study and Preclinical Data on Next-Gen Conditioning Agent MP0621 at ASH 2024
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
Molecular Partners Presents Preclinical Proof-of-Concept for CD3 Switch-DARPin T Cell Engager, Clinical Biomarker Analyses for MP0317 at SITC 2024
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
Molecular Partners Announces Upcoming Poster Presentations at the 65th ASH Annual Meeting and Exposition
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
Molecular Partners Q3 2024 Interim Management Statement: Multiple Updates Across Portfolio, Radio-DARPin candidate MP0712 preparing for clinical entry, MP0533 Phase 1 on-going
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
Molecular Partners Announces Pricing of $20 Million Underwritten Offering
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
Molecular Partners and Orano Med Present Additional Positive Preclinical Data Supporting DLL3 Targeting Radio-DARPin Therapeutic Candidate MP0712 at EANM 2024
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
Molecular Partners and Orano Med Strengthen Agreement to Co-Develop 212Pb-Based Radio-DARPin Therapeutics
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
Molecular Partners Announces upcoming poster presentations at the 2024 SITC Annual Meeting
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
Molecular Partners Announces Upcoming Top-Rated Oral Presentation on MP0712, a ²¹²Pb-labeled Radio-DARPin Therapeutic targeting DLL3 for Small Cell Lung Cancer co-developed with Orano Med, at EANM 2024
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
Molecular Partners Reports H1 2024 Corporate Highlights and Financials
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
Molecular Partners to Present at The TD Cowen Radiopharmaceutical Innovation Summit
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
Molecular Partners Presents Positive Preclinical Data for First Switch-DARPin Candidate MP0621 at EHA 2024
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
Molecular Partners and Orano Med Share Positive Preclinical Data of their DLL3-Targeting Radio-DARPin Therapy (RDT) Candidate MP0712 at SNMMI 2024
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.